Advertisement

x

Mathews Journal of Pharmaceutical Science

2474-753X

Publication Ethics

Mathews Open Access Journals follow certain ethical standards to make sure high-quality scientific publications, to attain public confidence in scientific findings.

Plagiarism/ Duplicate Submission: Mathews Open Access Journals firmly encourages original manuscripts and must not use the words, figures, or ideas of others without attribution. All sources must be cited at the point they are used, and reuse of wording must be limited and be attributed or quoted in the text. The content should not be submitted/ published elsewhere with other publishing groups. Our quality control teams check for the plagiarism through software to detect the overlapping of content and similar text in submitted manuscripts. Manuscripts that are found to have been plagiarized from a manuscript by other authors, whether published or unpublished, will be rejected and the authors may incur sanctions. Any published articles may need to be corrected or retracted.

Data Fabrication and Falsification: If the submitted manuscripts are found to have either fabricated or falsified research work, i.e. methods, experimental results, including the manipulation of images will be immediately rejected.

Conflicts of Interest: Authors must declare all potential interests in a ‘Conflicts of interest’ section, which should explain why the interest may be a conflict. If there are none, the authors should state “The author(s) declare(s) that there are no conflicts of interest regarding the publication of this paper.” Submitting authors are responsible for coauthors declaring their interests.

Human and Animal Rights: Ethical clearance documents need to be provided if applicable. The work involving animal models and human volunteers need to submit the necessary statements.

In the above publication ethical cases if the violations are found, the editorial office is authorized to take action accordingly.

Recently Published Articles
Research Article

Regulatory Update on eSubmissions in Balkans

Published : 01st April 2024
Author : Marjan Dzeparoski1,2,*
Citation : Dzeparoski M. (2024). Regulatory Update on eSubmissions in Balkans. Mathews J Pharma Sci. 8(1):26.

Research Article

Investigating the Potential of Nilotinib and its Derivatives in Targeting Tau Protein Hyperphosphorylation for Alzheimer's Disease Treatment

Published : 11th December 2023
Authors : Aria Hajihassan1, Atena Zandi1, Ghazal Esmaeili1, Mostafa Norizadeh2,3,*
Citation : Hajihassan A, et al. (2023). Investigating the Potential of Nilotinib and its Derivatives in Targeting Tau Protein Hyperphosphorylation for Alzheimer's Disease Treatment. Mathews J Pharma Sci. 7(4):25.

Research Article

Quality of Life and Medication Adherence in Rheumatoid Arthritis Patients

Published : 25th November 2023
Authors : Qadeer Ahmed, Muhammad Talha, Umer Ishtiaq, Saba Khurshid, Kaif Akbar, Urwa Amir, Muhammad Rehan, Ovais Ullah Shirazi, Shahid Latif, Zunaira Akbar, Iram Batool, Ali Akhtar*, Samreen Fatima
Citation : Ahmed Q, et al. (2023). Quality of Life and Medication Adherence in Rheumatoid Arthritis Patients. Mathews J Pharma Sci. 7(4):24.

Case Report

Desensitization in a Patient with Hypersensitivity to the Iodinated Contrast Medium Iopromide: A Clinical Case Report

Published : 03rd November 2023
Authors : Dadier Antonio Arroyo1,2,*, Linda Atencio1, Jorge Pérez Velásquez3, María Camila Coronado1, Meribeth Henry4, Maria Alejandra Suarez2, Daniela Katerine Rivera2
Citation : Arroyo DA, et al. (2023). Desensitization in a Patient with Hypersensitivity to the Iodinated Contrast Medium Iopromide: A Clinical Case Report. Mathews J Pharma Sci. 7(3):23.

Editorial Article

We Continue to Battle with Diseases that are Difficult to Diagnose and Cure in the 21st Century

Published : 17th October 2023
Author : Raúl Isea*
Citation : Isea R. (2023). We Continue to Battle with Diseases that are Difficult to Diagnose and Cure in the 21st Century. Mathews J Pharma Sci. 7(3):22.

Research Article

Four-Week Safety and Acceptability Study of 15% Bromelain Topical Lotion: An Open Label, Non-Comparative, Triple-Arm Study

Published : 11th October 2023
Authors : Allen B Richon1,*, Merry Ambos Richon2
Citation : Richon AB, et al. (2023). Four-Week Safety and Acceptability Study of 15% Bromelain Topical Lotion: An Open Label, Non-Comparative, Triple-Arm Study. Mathews J Pharma Sci. 7(3):21.

Indexed
Root Indexing
WolrdCat
J Gate
Directory of Research Journals Indexing
International Scientific Indexing
Genamics JournalSeek
Scientific Indexing Services
International Committee of Medical Journal Editors
Scilit
CiteFactor
Google Scholar
Subscribe

Subscribe to our RSS feed, be in touch with our articles, news, videos, reebies.

Antispam Code Generate new code

Creative Commons License

© 2015 Mathews Open Access Journals. All Rights Reserved.

Open Access by Mathews Open Access Journals is licensed under a
Creative Commons Attribution 4.0 International License.
Based On a Work at Mathewsopenaccess.com